Merck & Co. stock trades 0.46 percent above its Xetra close
Published on 10/25/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrial Results And Upcoming Dates
- Merck and Moderna reported INTerpath-001 melanoma results on October 22, 2026, including a 42 percent reduction in recurrence or death risk.
- Merck & Co. stock trades in weekend trading at EUR 129.81 at 5:36 p.m. CEST on October 25, 2026, 0.46 percent above the Xetra close of October 23, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Merck & Co. stock trades in weekend trading at Lang & Schwarz at EUR 129.81 at 5:36 p.m. CEST on October 25, 2026, 0.46 percent above the Xetra close of October 23, 2026, at EUR 129.22.
Market context: Market report S&P 500.
Weekend trading
The current indication is EUR 129.81 at Lang & Schwarz. The move is EUR 0.59 above the Xetra close of October 23, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Merck & Co. stock.
Melanoma trial results
On October 22, 2026, Merck and Moderna announced detailed results from the Phase 3 INTerpath-001 trial. In the primary pre-specified analysis, intismeran combined with KEYTRUDA reduced the risk of recurrence or death by 42 percent compared with KEYTRUDA alone. The combination also reduced the risk of distant metastasis or death by 38 percent. Merck.com said the study remains ongoing to evaluate overall survival and other endpoints.
Next Xetra session
The next Xetra session is scheduled for October 26, 2026. Merck’s announcement said the INTerpath-001 results would be presented during the European Society for Medical Oncology Congress 2026.
